http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108743939-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate | 2018-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108743939-B |
| titleOfInvention | Cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant carrying antigen, MPLA and IMQ together, and preparation method and application thereof |
| abstract | The invention relates to a cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant carrying antigens, MPLA and IMQ, a preparation method and application thereof, wherein the vaccine adjuvant carries a TLR7 agonist imiquimod on a hydrophobic inner core, carries a TLR4 agonist monophosphoryl lipid A on a phospholipid layer, adsorbs the antigens through cationic phospholipid DOTAP in the phospholipid layer, protects the antigens through hybrid nanoparticles and improves the uptake of dendritic cells to the antigens, and obviously enhances the immune response after the antigens are stimulated and obviously improves the antigen cross presentation through the TLR agonist; the hybrid nanoparticles can be used as a vaccine adjuvant to simultaneously carry antigens and different types of TLR agonists, can deliver the antigens in multiple immune ways, promote DC activation and maturation, improve cross presentation level, generate strong T cell killing effect, induce cytokine secretion, generate long-acting memory T cell reaction and have better prevention capability on tumors. |
| priorityDate | 2018-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.